Core Insights - The company presented data on HTD1801 at the 58th American Society of Nephrology (ASN) annual meeting, highlighting its potential kidney benefits in patients with mild renal impairment [1] - HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) designed to address cardiorenal metabolic system diseases (CKM) through a dual mechanism of activating AMPK and inhibiting NLRP3 [1] - The data is based on a pooled analysis from two Phase III clinical studies (SYMPHONY 1 & 2; N=956) involving patients with type 2 diabetes (T2DM) [1] Summary by Category Clinical Results - In patients with mild renal impairment, HTD1801 significantly improved eGFR compared to placebo, with a positive slope in eGFR during treatment [2] - In patients with hyperfiltration, HTD1801 reduced eGFR compared to placebo, suggesting a potential to restore kidney function to normal levels [2] - HTD1801 did not show adverse effects on blood pressure, blood sodium, or blood potassium levels [2]
2025 ASN最新突破性专场|君圣泰医药-B(02511)展示HTD1801肾脏获益数据